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Valorization is the estimation in as much the published scientific work can be 
utilized in the practice and depends on the category of performed research. 
Whereas data from clinical research, e.g. clinical trials, or translational research 
might impact clinical practice earlier, it is well know that research data gained from 
basic research might take longer before they will be transferred or implemented 
in the clinical practice. Here, I will point out how the main results of this thesis are 
very likely to improve the diagnosis and clinical management of Merkel cell 
carcinoma (MCC) in the near future. 
Depending on the localization, the rare and aggressive skin cancer MCC is mostly 
detected at late stage III and IV3. At stage III MCC is metastasized to local lymph 
nodes. At stage IV it is either metastasized to distant lymph nodes or solid organs 
e.g. lung3. In the latter it might possibly difficult to distinguish MCCs from small
cell lung cancer (SCLC). In chapter 3, we described the complete absence of RE-
1 silencing transcription factor REST as well as the achaete-scute family BHLH
transcription factor 1 (ASCL1) in MCC. Contrariwise, ASCL1 was shown to be
expressed in 70% of SCLCs4. Moreover, the hematopoietic program and the
presence of splice variants of the paired box protein PAX5 in MCC which we
showed is unique for MCC (chapter 5) might be also used in as marker to
distinguish SCLC from MCC.
The main focus of this thesis was to get more insight into the cellular origin of
MCC. Irrespective of the cellular origin of MCC, it is expected that the results of
this research will contribute to the understanding of its pathogenesis, ultimately
possibly leading to novel treatment options. Based on the results presented in this
dissertation we now know that the cellular origin should have stem cell activity, is
very likely to be of hematopoietic origin and is characterized by a significant,
however partially defective hematopoietic PAX5 transcription program. Thus, the
pre-pro B-cell is currently the most appropriate candidate for the cellular origin.
The gained knowledge about the cellular origin can now be applied to the
treatment of MCC. Because of its rareness clinical trials on MCC treatment of
more than 100 people cohorts are rare. Therefore, the most clinical trials for the
treatment of MCC are starting from phase 2 or phase 3 where MCC patients are
included in a general cohort among others with solid tumors like cutaneous
squamous cell carcinoma. A successful example of a nowadays approved A
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compound for the treatment of MCC is Avelumab which was assessed in clinical 
trial phase 2 in 200 MCC patients which showed an overall response rate of 50 to 
70% 5-7. In chapter 7 we used our gained knowledge about the early B-cell 
phenotype of MCC and treated the cells with the promising combination of the 
BCL-2 family member inhibitor Navitoclax and the PI3K p110 Alpelisib. The 
compounds induced only in combination a stagnation in cell viability. Both 
compounds are in individual clinical trials phase 2 7-9. Therefore, the costs for the 
first phase of the clinical trial of about 475,000€ in the Netherlands can be 
skipped11. The costs of about 11,379€ per patient in clinical trial 2 has still to be 
considered.12 Clinical trial phase II takes several months with a group of at least 
100 people. For MCC to get that many cases are difficult, therefore international 
cooperation like it was performed with Avelumab are necessary to realize a 
significant evaluation of the synergism of these compounds in the clinic. 
Therefore, a clinical trial phase 2 to evaluate the efficacy of Navitoclax/Alpelisib 
might be conducted within several months and might be approved by the FDA.  
After successful treatment, the patients have to be evaluated for recurrence of the 
cancer by follow-up care. The easiest way is to use biological fluids like blood. 
The younger DNA methylation age (DNAmAge) of blood cells compared to the 
chronological age have a significant correlation2. In chapter 2 we characterized 
that MCCs have a significantly younger DNA methylation age (DNAmAge) 
compared to the chronological age of the MCC patients. Therefore, it might be 
possible to establish an assay to determine the DNAmAge of DNA located in the 
blood. For this screening method only 10 ng of purified DNA is enough for 
enrichment using the capture enrichment Illumina technology and hybridized with 
the 353 CpG sites of the Horvath’s clock. If the DNAmAge is significant younger, 
it is most likely that the patient has aberrant cells and the patient has to be 
screened for recurrence of the cancer.  
The knowledge about the synergism of the Navitoclax/Alpelisib combination can 
be therefore transferred into clinical practice. The combination would not be tested 
on MCC if we had not observed the hematopoietic pre-pro B-cell origin of MCC. 
Moreover, the DNAmAge determination blood screening method might be also 
utilized in the clinic for the follow-up control of MCC. Therefore, this dissertation 
A
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has gained important data which potentially will be successfully translated into a 
pre-clinical setting and transferred further into the clinical practice.  
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